iCAD, Inc. (Nasdaq: ICAD), an industry leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced the commercial availability of iCAD’s VeraLook CTC CAD solution integrated into Vital Images’ products as a result of a strategic partnership agreement signed earlier this year. Vital Images is a Toshiba Medical Systems Group Company and the leading provider of advanced visualization and analysis solutions for healthcare providers. With this agreement, iCAD’s VeraLook CTC CAD solution is now available as part of Vital Images’ products worldwide.
This collaboration will provide clinicians with computer-aided detection (CAD) tools for the review and analysis of CT Colonography (CTC) images and will enhance the speed and accuracy of cancer detection. iCAD’s advanced image analysis technologies enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. Vital Images’ scalable solutions consist of advanced visualization tools, clinical applications, and data management systems.
“The vast majority of colorectal cancer deaths are preventable with early screening, and CT Colonography has the potential to eliminate many of the traditional barriers to routine colorectal screening,” said Ken Ferry, President and CEO of iCAD. “We are enthusiastic about the broad potential of this agreement and look forward to working with Vital Images to leverage our combined powerful visualization, detection, and workflow tools to significantly improve colon cancer detection and enhance workflow for radiologists and their patients throughout the world.”
VeraLook is designed to detect and highlight potential polyps during CTC examinations. Extensive testing with radiologists has demonstrated that the use of VeraLook improved reader sensitivity to all colonic polyps in a statistically significant manner – particularly for smaller, more easily missed polyps and pre-cancerous polyps which can develop into malignancies over time. VeraLook has also demonstrated high standalone sensitivity to detecting polyps, while generating a low number of clinically acceptable false positive marks on CTC images.